Journal of Medicinal Chemistry · 2024 · 35 citations · 42 references
PharmacyMedicinal ChemistryPharmacologyDrug DesignDrug DiscoveryOcular PharmacologyEnzyme InhibitionGlaucomaLead Compound DesignOcular PharmacodynamicsRetinal PharmacotherapyAnti-glaucoma PharmacotherapyAntiglaucoma TherapyCarbonic Anhydrase FunctionCarbonic Anhydrase InhibitorsCarbonic Anhydrase TargetsIsoform DiscoveryRetinal Drug TargetingRetinal Pharmacology
As a progressive neuropathic condition, glaucoma can cause lifelong blindness if left untreated. Novel phenylpyridazine-tethered sulfonamides were designed as selective inhibitors for carbonic anhydrase (CA) isoform II to find effective therapeutic agents for glaucoma. Subsequently, the target inhibitors were synthesized and assessed for their inhibitory action against cytosolic CA I and II. Interestingly, the synthesized molecules poorly inhibited CA I while exhibiting low subnanomolar potency against CA II. Compound 7c disclosed the most potent activity (IC 50 = 0.63 nM) with high selectivity against CA II (605-fold than acetazolamide selectivity). Moreover, compound 7c also showed significant in vivo IOP-reducing properties in the in vivo model of glaucoma. Furthermore, the binding of compound 7c to CA II was assessed at the molecular level, exploiting the molecular docking approach.
42
Alessio Nocentini, Marta Ferraroni, Fabrizio Carta et al. · Journal of Medicinal Chemistry · 2016 · 109 citations · Full text
Jean‐Marie Contreras, Isabelle Parrot, Wolfgang Sippl et al. · Journal of Medicinal Chemistry · 2001 · 105 citations · Full text